Scarica l'app Stockscreener
13.51
2.10%
-0.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$13.80
Aprire:
$13.89
Volume 24 ore:
8.96M
Relative Volume:
0.90
Capitalizzazione di mercato:
$15.56B
Reddito:
$14.29B
Utile/perdita netta:
$-3.51B
Rapporto P/E:
-4.5637
EPS:
-2.9603
Flusso di cassa netto:
$1.85B
1 W Prestazione:
-4.59%
1M Prestazione:
-14.33%
6M Prestazione:
+35.64%
1 anno Prestazione:
+50.45%
Intervallo 1D:
$13.48
$13.97
Intervallo di 1 settimana:
$13.48
$14.52
Portata 52W:
$6.85
$16.47
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
13.51 | 15.56B | 14.29B | -3.51B | 1.85B | -2.9603 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.67B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 33.27B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.12 | 23.50B | 3.18B | 1.33B | 1.04B | 27.90 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-01-16 | Aggiornamento | Argus | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
Henrietta Lacks family settles lawsuit against Viatris over cell use - WBFF
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
UBS and BofA Lift Price Targets on Viatris (VTRS) - Insider Monkey
Assessing Viatris (VTRS) Valuation After Recent Share Price Pullback - simplywall.st
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal - MSN
Viatris' Mylan Drops Claims Disputing Novo's Patent-Infringement Suit - marketscreener.com
Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst - TipRanks
Viatris resolves case over use of woman’s cancer cells (VTRS) - Seeking Alpha
Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research - Reuters
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha
Viatris Collaborates With GoodRx for Discounts of Up to 85% on Medications - marketscreener.com
Lipitor and Viagra discounts: GoodRx deal cuts brand drugs to $0–$4 - Stock Titan
Viatris Stock Analysis: Strong 6-Month Gains vs. Poor 5-Year FundamentalsNews and Statistics - IndexBox
Trading Systems Reacting to (VTRS) Volatility - Stock Traders Daily
Propranolol Market Overall Study Report 2026-2033 | Teva - openPR.com
Viatris (VTRS) director exercises RSUs and receives new stock award - Stock Titan
Viatris (VTRS) director adds shares as RSUs vest and new grant issued - Stock Titan
Viatris (VTRS) director settles RSUs into shares and receives 15,890-unit grant - Stock Titan
[Form 4] Viatris Inc Insider Trading Activity - Stock Titan
Viatris (VTRS) director acquires shares and new RSUs via awards - Stock Titan
Viatris (VTRS) director reports 684 common shares via trusts - Stock Titan
Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings? - Finviz
Viatris (VTRS): Should You Buy, Sell, or Hold After Q4 Results? - Bitget
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris Inc.: - marketscreener.com
Viatris Inc. (VTRS) provides updates on four recent regulatory milestones - MSN
Viatris Eyes Specialty Shift As FDA Reviews MR-141 Presbyopia Drug - Yahoo Finance
Viatris tops forecasts as earnings and revenue beat expectations - MSN
Goldman Sachs Adjusts Price Target on Viatris to $14 From $13, Maintains Neutral Rating - marketscreener.com
FDA Review Of MR-141 Puts Viatris Ophthalmic Growth Story In Focus - Sahm
Better Value & Growth: LLY, JNJ Top Viatris Stock - Trefis
Viatris (VTRS) officer nets stock from RSU and PRSU vesting - Stock Titan
Ex-Dividend Reminder: Alphabet, Constellation Energy and Viatris - Nasdaq
Viatris Stock Hits Day Low of $15.14 Amid Price Pressure - Markets Mojo
Viatris, Inc. Hits New 52-Week High at USD 16.46 - Markets Mojo
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Nasdaq
Viatris Unit Can't Ax Patent For Anemia Drug Evrenzo - Law360
Generic Pharma Q4 2025 Earnings Review: Revenue Beat, Stock DeclineNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive - FinancialContent
VTRS Financials: Income Statement, Balance Sheet & Cash Flow | Viatris Inc Ord Shs - Stock Titan
A Look At Viatris (VTRS) Valuation After Earnings, 2026 Guidance And MR-141 FDA Review - simplywall.st
Viatris (VTRS) Delivers Solid 2025 Growth and Robust Cash Flow at Deep Value - Finviz
Viatris Inc. (VTRS) Stock Report: Navigating the Healthcare Giant’s 3.22% Dividend Yield and Revenue Growth - DirectorsTalk Interviews
Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4 - Finviz
Viatris Earnings Call Highlights Slow Growth, Cash Strength - TipRanks
UBS Raises Viatris (VTRS) Price Target as Cost Savings and Growth Outlook Improve - Insider Monkey
UBS raises Viatris stock price target to $20 on cost savings - Investing.com India
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and more - Medical Marketing and Media
UBS Adjusts Viatris Price Target to $20 From $18, Maintains Buy Rating - marketscreener.com
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.57%
1.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):